AZ shares drop on new CEO's buyback move; Horizon salesforce amped up for Rayos launch;

@FiercePharma: Kaiser, Washington Post team up for look at co-pay coupons. Upshot: Good for patient, but not for payer. More | Follow @FiercePharma

> AstraZeneca ($AZN) stock slid after its brand-new CEO suspended share buybacks, pending a strategy review; analysts expected downgrades to the company's stock. Report | Report

> Horizon Pharma has officially expanded its sales force to 150 from 80, to amp up its promotions for its lead product, Duexis, and to launch its new product, Rayos. Report

> Merck Serono unveiled details of the disappointing results from a recent trial testing its cancer drug Erbitux in patients with gastric cancer. Report

> A U.S. judge extended an injunction against Merz Aesthetics' marketing of its Botox competitor Xeomin; the order also restricts the company's dermal-fillers sales. Report

> U.K. regulators licensed Allergan's Botox injection for management of urinary incontinence in patients with spinal cord injury or multiple sclerosis. Report

> BASF said it would move the global headquarters of its pharma ingredients and services business to Florham Park, NJ, from Switzerland. Report

Medical Device News

 @FierceMedDev: Out of the mind of a Ph.D student- a new test for glucose levels using sweat, urine or tears. More | Follow @FierceMedDev

 @MarkHFierce: The FDA wants a judge to dismiss a lawsuit by ex-device center employees accusing the agency of spying on them. Article | Follow @MarkHFierce

 @DamianFierce: Welch Allyn touts its easy-to-use, iPhone-based eye exam device. Story | Follow @DamianFierce

> FDA cites Zimmer for hip replacement manufacturing shortfalls. Article

> AutoGenomics gives IPO another go with $65M offering. Story

Biotech News

 @FierceBiotech: J&J, Lilly and Boehringer tout data on SGLT2 drugs for diabetes. More | Follow @FierceBiotech

 @JohnCFierce: BioInvent in Sweden takes out the ax again and chops 20 jobs, the survivors are focusing on cancer drugs. Release | Follow @JohnCFierce

 @RyanMFierce: Sanofi/Genzyme's late-stage Gaucher pill hits goal in late-stage study, next-gen treatment for rare LSD. More | Follow @RyanMFierce

> J&J, Astellas strike potential $945M deal for oral RA drug. Story

> ArQule shares nosedive with failure of key PhIII trial for lung cancer drug. Article

Pharma Manufacturing News

> Drugs for illegal Internet pharmacy made in India, Mexico. Report

> China's Tianyin moves ahead with plant as profit plummets. Story

> FDA tries to teach consumers of Internet dangers. Article

Biotech Research News

> Study: Impropriety affects retracted research more than honest mistakes. Article

> New drug target could halt age-related immune system declines. Story

> UC Davis: Induced pluripotent stem cells resemble cancer cells. Report

> Avatar mice up ante for personalized drug treatment research. Item

And Finally... Ex-GlaxoSmithKline ($GSK) in-house counsel Lauren Stevens, acquitted of charges of making false statements to FDA, said "the criminalization of the practice of law is here." Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.